The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Wu, Xing ^a   Cai, Ming ^a   Ji, Fang ^a   Lou, Lie ming ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antisense oligonucleotide; COX 2; Invasion; Osteosarcoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLOOXYGENASE 2; MESSENGER RNA; UROKINASE; UROKINASE RECEPTOR;

ANTISENSE THERAPY; ARTICLE; ASSAY; BOYDEN TRANSWELL ASSAY; CELL INVASION; CELL INVASION ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

EID: 84899142653     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-27     Document Type: Article

References (23)

1. Kempf-Bielack B, Bielack SS, Jurgens H. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005, 23:559-568.
2. Faqioli F, Biasin E, Mereuta OM, Murara M, Luksch R, Ferrari S. Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant 2008, 41(Suppl 2):S131-S134.
3. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008, 14:2962-2969. 10.1158/1078-0432.CCR-07-1992, 2830718, 18483362.
4. Dannenberg AJ, Lippman SM, Mann JR. Cyclooxygenase-2 and epidermal growth actor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23:254-266. 10.1200/JCO.2005.09.112, 15637389.
5. Blanke C. Role of COX-2 inhibitors in cancer therapy. Cancer Invest 2004, 22:271-282. 10.1081/CNV-120030216, 15199610.
6. Huang SP, Wu MS, Shun CT, Wang HP, Hsieh CY, Kuo ML. Cyclooxygenase-2 increases hypoxia-inducible hctor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 2005, 12:229-241. 10.1007/s11373-004-8177-5, 15864753.
7. Cressey R, Pimpa S, Tontrong W, Watananupong O, Leartprasertsuke N. Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Lett JT 2006, 233:232-239.
8. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004, 31:2-11.
9. Oqino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008, 14:8221-8227. 10.1158/1078-0432.CCR-08-1841, 2679582, 19088039.
10. Singh B, Cook KR, Vincent L, Hall CS, Berry JA, Multani AS. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 2008, 147:240-246. 10.1016/j.jss.2008.02.026, 18498876.
11. Brown JR, Dubois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004, 10:4266-4269.
12. Dickens DS, Cripe TP. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol 2003, 25:709-714. 10.1097/00043426-200309000-00007, 12972806.
13. Shetty P, Velusamy T, Bhandary YP, Liu MC, Shetty S. Urokinase receptor expression involves tyrosine phosphorylation of phosphoglycerate kinase. Mol Cell Biochem 2010, 335:235-247. 10.1007/s11010-009-0273-4, 19784757.
14. Dass CR, Choong PF. uPAR mediates anticancer activity of PEDF. Cancer Biol Ther 2008, 7:1262-1270. 10.4161/cbt.7.8.6265, 18487955.
15. Sheng S. The feasibility of uPA/uPAR-targeting strategies in cancer treatment. Cancer Biol Ther 2008, 7:660-662. 10.4161/cbt.7.5.6076, 18756623.
16. Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, Zlobec I. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol 2010, 41:70-78. 10.1016/j.humpath.2009.05.013, 19740518.
17. Cheng X, Shen Z, Yin L, Lu SH, Cui Y. ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J Biol Chem 2009, 284:30897-30906. 10.1074/jbc.M109.011213, 2781489, 19717562.
18. Jo M, Thomas KS, Takimoto S, Gaultier A, Hsieh EH, Lester RD. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene 2007, 26:2585-2594. 10.1038/sj.onc.1210066, 17043637.
19. Mahanivong C, Yu J, Huang S. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator. Mol Carcinog 2007, 46:165-175. 10.1002/mc.20249, 17186542.
20. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells byactivation of urokinase receptor-dependent cell signaling. J Biol Chem 2009, 284:22825-22833. 10.1074/jbc.M109.023960, 2755690, 19546228.
21. Gårdsvoll H, Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem 2007, 282:13561-13572. 10.1074/jbc.M610184200, 17355965.
22. Guthaus E, Schmiedeberg N, Burgle M. The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction. Recent Results Cancer Res 2003, 162:3-14. 10.1007/978-3-642-59349-9_1, 12790317.
23. Andreasen PA, Egelund R, Petersen HH. The Plasminogen activation system in tumor growth invasion and matastasis. Cell Mol Life Sci 2000, 57:25-40. 10.1007/s000180050497, 10949579.